Literature DB >> 2991901

Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

M P Stoppelli, A Corti, A Soffientini, G Cassani, F Blasi, R K Assoian.   

Abstract

The purified amino-terminal fragment (ATF) of human urokinase plasminogen activator (residues 1-135), which is not required for activation of plasminogen, binds with high affinity to specific plasma membrane receptors on U937 monocytes. Intact urokinase efficiently competes for 125I-labeled ATF binding; 50% competition occurs with 1 nM urokinase. A large part of receptor-bound urokinase remains on the cell surface for at least 2 hr at 37 degrees C. Differentiation of U937 monocytes into macrophage-like cells specifically increases ATF binding 10- to 20-fold. These results suggest an important role for urokinase in monocyte/macrophage biology: the native enzyme binds to the cells with the amino-terminal domain; the catalytic, carboxyl-terminal domain remains exposed on the cell surface to stimulate localized proteolysis and facilitate cell migration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991901      PMCID: PMC390473          DOI: 10.1073/pnas.82.15.4939

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Urokinase an activator of plasminogen from human urine. I. Isolation and properties.

Authors:  J PLOUG; N O KJELDGAARD
Journal:  Biochim Biophys Acta       Date:  1957-05

2.  Mathematics of hormone-receptor interaction. I. Basic principles.

Authors:  D Rodbard
Journal:  Adv Exp Med Biol       Date:  1973       Impact factor: 2.622

3.  Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization.

Authors:  C R Savage; S Cohen
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

4.  Phagocytosis by human monocytes.

Authors:  M J Cline; R I Lehrer
Journal:  Blood       Date:  1968-09       Impact factor: 22.113

5.  Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways.

Authors:  P Early; J Rogers; M Davis; K Calame; M Bond; R Wall; L Hood
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

6.  Autocrine secretion and malignant transformation of cells.

Authors:  M B Sporn; G J Todaro
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

7.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

8.  Plasminogen activator is an apparent lymphocyte mitogen.

Authors:  S D Cohen; E Israel; B Spiess-Meier; M A Wainberg
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Secretion of plasminogen activator by stimulated macrophages.

Authors:  J C Unkeless; S Gordon; E Reich
Journal:  J Exp Med       Date:  1974-04-01       Impact factor: 14.307

10.  Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration.

Authors:  L Ossowski; J P Quigley; G M Kellerman; E Reich
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

View more
  112 in total

1.  Isolation and characterization of cell lines with reduced urokinase binding.

Authors:  H K Lau; J M Teitel; M Kim
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

4.  Differential expression of Plg-RKT and its effects on migration of proinflammatory monocyte and macrophage subsets.

Authors:  Barbara Thaler; Nagyung Baik; Philipp J Hohensinner; Johanna Baumgartner; Adelheid Panzenböck; Stefan Stojkovic; Svitlana Demyanets; Ihor Huk; Gersina Rega-Kaun; Christoph Kaun; Manfred Prager; Michael B Fischer; Kurt Huber; Walter S Speidl; Robert J Parmer; Lindsey A Miles; Johann Wojta
Journal:  Blood       Date:  2019-06-20       Impact factor: 22.113

5.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

6.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

7.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

8.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

9.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

10.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.